FDA Issues Guidance on Clinical Trials Amid COVID-19 Pandemic


FDAlogo 300The global COVID-19 pandemic will likely impact current and planned clinical trials, including those using focused ultrasound. The guidance released by the US Food and Drug Administration (FDA) acknowledges this likelihood and focuses on the safety of trial participants and medical staff while also maintaining compliance and good clinical practice. The considerations outline alternative methods of data collection, such as via phone or email, and additional safety monitoring.

Read the Guidance >

See Additional Relevant COVID-19 Resources >